Skip to main content
PMC home page
Frontiers in Microbiology logoLink to Frontiers in Microbiology
. 2017 Dec 19;8:2537. doi: 10.3389/fmicb.2017.02537

Potential Links between Hepadnavirus and Bornavirus Sequences in the Host Genome and Cancer

Tomoyuki Honda 1,*
PMCID: PMC5742130  PMID: 29312227

Abstract

Various viruses leave their sequences in the host genomes during infection. Such events occur mainly in retrovirus infection but also sometimes in DNA and non-retroviral RNA virus infections. If viral sequences are integrated into the genomes of germ line cells, the sequences can become inherited as endogenous viral elements (EVEs). The integration events of viral sequences may have oncogenic potential. Because proviral integrations of some retroviruses and/or reactivation of endogenous retroviruses are closely linked to cancers, viral insertions related to non-retroviral viruses also possibly contribute to cancer development. This article focuses on genomic viral sequences derived from two non-retroviral viruses, whose endogenization is already reported, and discusses their possible contributions to cancer. Viral insertions of hepatitis B virus play roles in the development of hepatocellular carcinoma. Endogenous bornavirus-like elements, the only non-retroviral RNA virus-related EVEs found in the human genome, may also be involved in cancer formation. In addition, the possible contribution of the interactions between viruses and retrotransposons, which seem to be a major driving force for generating EVEs related to non-retroviral RNA viruses, to cancers will be discussed. Future studies regarding the possible links described here may open a new avenue for the development of novel therapeutics for tumor virus-related cancers and/or provide novel insights into EVE functions.

Keywords: hepatitis B virus, endogenous viral elements, cancer, borna disease virus, non-coding RNAs, LINE-1, retrotransposon

Introduction

Viruses can deposit their sequences into the host genome during infection. Consistently, animal genomes contain many viral-related sequences, called endogenous viral elements (EVEs) (Katzourakis and Gifford, 2010; Holmes, 2011; Parrish and Tomonaga, 2016). EVEs are mainly derived from ancient retroviruses because retroviruses require the integration of their DNAs into the host genome for replication. In addition to retroviruses, DNA and non-retroviral RNA viruses can sometimes become integrated into the host genome, despite the fact that integration events are not required for the viral life cycle. In particular, sequences of non-retroviral RNA viruses seem to have been integrated into the host genome possibly by machineries of a host retrotransposon, long interspersed nuclear element 1 (LINE-1, or L1) (Horie et al., 2010). The integration events of viral sequences occur not only in somatic cells but also in germ line cells. If the integration event occurs in germ line cells, the integrated viral sequences become inherited as EVEs. Thus, the integration of viral sequences into the genome of germ line cells is an essential first step for generating EVEs.

Viral integration can have oncogenic potential via several mechanisms (Figure 1A). First, the inserted sequences in the vicinity of an oncogene may function as a promoter for the oncogene. Second, such events may inactivate tumor suppressor genes via insertional mutagenesis. Third, such integrated sequences may induce genomic instability via homologous recombination (Hino et al., 1991). Fourth, the integrated sequences may epigenetically regulate the host gene expression landscape, leading to cancer formation and spreading (Zhao et al., 2016). Fifth, such sequences may produce an oncogenic protein or non-coding RNA (Lau et al., 2014).

FIGURE 1.

FIGURE 1

Open in a new tab

The possible contribution of viral sequences in the genome to cancer development. (A) Overview of possible functions of genomic viral sequences. Viral sequences in the genome could function as a gene regulatory DNA element (red), a functional RNA (green) or a protein (blue), all of which can contribute to cancer development. (B) HBV insertions in the genome. HBV insertions may enhance TERT promoter activity, have a recombinogenic effect or produce a viral-host chimeric RNA with an oncogenic potential. (C) EBLNs in the genome. The hsEBLN-2 protein may be involved in mitochondrial function, whereas the hsEBLN-1 protein may regulate microtubules. The hsEBLN-1 RNA has also been shown to regulate tumor-related genes.

Regarding the relationship between viruses and cancers, many excellent reviews have been published about the links between endogenous retroviruses or tumor viruses and cancers (Suntsova et al., 2015; Gonzalez-Cao et al., 2016; Gramolelli and Ojala, 2017; McBride, 2017; Pancholi et al., 2017). On the other hand, few have dealt with the association between non-retroviral viral sequences in the genome and cancers. One of such studies has proposed that insertions of human papilloma virus contribute to cervical cancer formation through interrupting tumor suppressor or destabilizing chromosomes (Zhao et al., 2016). Here, I especially focus on the genomic sequences derived from two non-retroviral viruses, whose endogenization is already reported in animal genomes (Horie et al., 2010; Shen et al., 2016), and discuss the possibilities how these specific sequences could contribute to cancer formation. As DNA virus-related EVEs, EVEs derived from hepadnavirus and human herpesvirus 6 (HHV-6) are reported in animal genomes (Gravel et al., 2015; Shen et al., 2016). Because the link between HHV-6 insertions and cancer is not convincing at present, I will introduce current understanding regarding the roles of hepatitis B virus (HBV), a tumor-related hepadnavirus, insertions and hepatocellular carcinoma (HCC). Then, I will discuss the possible involvement of EVEs derived from ancient non-retroviral RNA virus sequences in cancers. Because endogenous bornavirus-like elements (EBLs) are the only non-retroviral RNA virus-derived EVEs found in the human genome thus far (Horie et al., 2010), I focus on the possible links between these elements and cancers although these links have not been demonstrated. EBLs are possibly generated in a retrotransposon-dependent manner. Therefore, I will finally propose the possible contribution of virus-retrotransposon interactions to cancers. This article aims to inspire future studies regarding the possible links described here, which may open a new avenue for understanding of the significance of viral insertions in the host genome.

A Potential Link Between HCC and HBV Insertions in the Genome

Hepatocellular carcinoma accounts for 80% of liver cancer, whose major causative agents are two hepatitis viruses, HBV and hepatitis C virus (HCV) (Jemal et al., 2011; Forner et al., 2012; Tateishi and Omata, 2012). HBV is a DNA virus that belongs to the Hepadnaviridae family (Beck and Nassal, 2007; Nguyen et al., 2008), while HCV is an RNA virus and belongs to the Flaviviridae family (Hijikata et al., 1991; Grakoui et al., 1993; Aly et al., 2012). Both viruses can cause chronic infections, which may increase the chance of horizontal viral gene transfer to the host genome (Parkin, 2006; Aly et al., 2012). Consistent with this idea, EVEs derived from an ancient hepadnavirus and an ancestor HCV have been identified in animal genomes although they are not in the human genome. The budgerigar genome contains two EVEs with the full-length genome of the ancient budgerigar hepadnavirus (Shen et al., 2016). The rabbit and hare genomes have fragments homologous to HCV genes, which might suggest the possibility that cDNA from an HCV ancestor was integrated into the host genome (Silva et al., 2012). Although HCV replicates without a known DNA intermediate stage, it is still possible that the sequences of non-retroviral RNA viruses are integrated into the host genome via host retrotransposon machineries as evidenced by several studies (Geuking et al., 2009; Horie et al., 2010). HCV cDNA has been reportedly detected in patients infected with HCV (Zemer et al., 2008), further supporting this possibility. However, the contribution of integration events of the HCV sequences to oncogenesis remains unclear.

On the other hand, insertions of the HBV sequences seem to be closely linked to HCC development because the frequency of HBV insertions in cancer tissue is larger than that in cancer-adjacent tissues (Ding et al., 2012; Jiang et al., 2012). So far, several genes that are recurrently targeted by HBV insertions have been reported (Ding et al., 2012; Fujimoto et al., 2012). It has been proposed that HBV insertions occur during chronic hepatitis and that some of the cells with HBV insertions can acquire growth advantages and initiate tumorigenesis (Ding et al., 2012). A possible oncogenic contribution of HBV insertions is modification of gene expression via insertions into the genomic regulatory region, genomic instability induced by recombination between integrated HBV sequences or production of oncogenic cellular-HBV chimeric proteins or non-coding RNAs (Figure 1B). One of the first cases is the recurrent insertion into the telomerase reverse transcriptase (TERT) gene (Ferber et al., 2003). TERT expression is a limiting factor in telomerase activation and its upregulation is thought to be a critical step in tumorigenesis (Ferber et al., 2003). HBV insertions in the promoter region of the TERT gene enhance its expression, which might be related to HCC development (Ding et al., 2012; Sung et al., 2012). The second possibility is supported by the observation that fragments containing the HBV sequences increase the recombination events (Hino et al., 1991).

The chimeric gene, HBx-L1, is an example of the third possible mechanism described above (Lau et al., 2014). HBx-L1 is a fusion gene of HBx, an HBV gene, and LINE-1, a host retrotransposon, produced by the HBV integration event, which is found in more than 20% of HBV-related HCC and correlates with a poor outcome (Lau et al., 2014). Knockdown of the HBx-L1 transcript reduces migratory and invasive properties of HBV-positive HCC cells. HBx-L1 overexpression confers a growth advantage and promotes cell migration and invasion via β-catenin/Wnt signaling, a major pathway in the oncogenesis of HBV-related HCC, regardless of its protein-coding potential (Lau et al., 2014). Thus, the HBx-L1 transcript is a chimeric long non-coding RNA (lncRNA) that promotes the HCC phenotype (Whittaker et al., 2010; Lau et al., 2014).

A Potential Link Between Cancers and Endogenous Bornavirus-Like Elements

Endogenous bornavirus-like elements are the only non-retroviral RNA virus-derived EVEs found in the human genome, although DNA virus-derived EVEs are also found in the human genome (Gravel et al., 2015). The majority of such elements are EBLs from the bornavirus nucleoprotein (N) gene (EBLNs), which appear to have originated from the reverse-transcription and integration of ancient bornavirus N mRNA (Horie et al., 2010). Among 7 Homo sapiens EBLNs (hsEBLNs) in the human genome, hsEBLN-2 is most closely linked to cancer. Whole exome sequencing using two sibling pairs of non-smokers with lung adenocarcinoma reveals that a truncated mutation in hsEBLN-2 is only detected in affected siblings (Renieri et al., 2014). The authors concluded that this mutation in hsEBLN-2 might predispose an individual to lung adenocarcinoma (Renieri et al., 2014). The loss of 3p12-p14 is recurrently observed in uterine cervical cancer, suggesting a strong selection advantage for the gene loss (Lando et al., 2013). hsEBLN-2 is highly down-regulated in cases with this gene loss (Lando et al., 2013). Gene ontology analysis of the genes associated with the loss, including hsEBLN-2, shows enrichment of tumorigenic pathways, such as apoptosis, proliferation and stress responses, suggesting that hsEBLN-2 might be a tumor suppressor. hsEBLN-2 is homologous to the bornavirus N gene but also contains an additional TOM20 recognition motif (F4LKLY8) at the N-terminal. Furthermore, the hsEBLN-2 protein was shown to be expressed and to interact with several other host proteins (Ewing et al., 2007). Because mitochondrial dysfunction is found in cancers (Lleonart et al., 2017), hsEBLN-2 might play important roles in mitochondrial function and then act as a tumor suppressor (Figure 1C).

hsEBLN-1 retains a long open reading frame (ORF) that encodes 366 amino acids, which is comparable with the full-length BDV N protein (Horie et al., 2010). Despite the overall homology between hsEBLN-1 and BDV N proteins, their subcellular localizations are different, suggesting that hsEBLN-1 may have acquired new or additional functions during millions of years of residence within the human genome (Honda and Tomonaga, 2013; Fujino et al., 2014). Recently, two studies have revealed the involvement of hsEBLN-1 in tumorigenic pathways, such as cell cycle transit, cell genome stability and apoptosis (He et al., 2016; Myers et al., 2016) (Figure 1C). Both studies demonstrated that hsEBLN-1 silencing increases the proportion of cells in the G2/M phase. hsEBLN-1 knockdown cells exhibit microtubule and centrosomal splitting defects (Myers et al., 2016). Proteomic analysis of the purified hsEBLN-1 complex identified several binding partners for hsEBLN-1 (Myers et al., 2016). Among these, TPR (Translocated Promoter Region) is a nuclear protein that regulates mRNA transport and mitotic spindles. Because hsEBLN-1 silencing impairs the nuclear envelope localization of TPR, improper localization of TPR may abrogate TPR function to regulate microtubules and thereby induces abnormal cell cycle progression. Indeed, TPR has been implicated in cancer development (Snow and Paschal, 2014). In addition to this, three genes upregulated after hsEBLN-1 silencing, RND3, OSMR, and CREB3L2, are closely linked to glioma (He et al., 2016). This observation raises the possibility that hsEBLN-1 may be involved in the development of some kinds of cancers, although no hsEBLN-1 mutations have been identified in cancer thus far.

We have previously demonstrated that hsEBLN-1 can modulate the expression of its neighboring gene, COMMD3 (Sofuku et al., 2015). When transcription from the hsEBLN-1 locus in the human genome was induced, expression of the COMMD3 gene was downregulated. The effect of hsEBLN-1 RNA expression on the COMMD3 locus was abrogated by treatment with siRNA against hsEBLN-1 RNA. These results suggest that hsEBLN-1 RNA may function as a lncRNA that scaffolds transcriptional and/or epigenetic repressors for the COMMD3 gene and suppress its expression. Although we cannot exclude the possibility that hsEBLN-1 functions as a cis-regulatory DNA element or a protein acting on this locus in trans, our data using siRNA and cytoplasmic localization of the hsEBLN-1 protein strongly suggest a role for hsEBLN-1 as a lncRNA (Fujino et al., 2014; Sofuku et al., 2015). The COMMD3 gene encodes a protein that can interact with and inhibit the NF-kB pathway (Burstein et al., 2005), which regulates type I interferons (IFNs), inflammatory cytokines, such as interleukin-1 (IL-1), IL-2, IL-6, IL-12, and tumor necrosis factor (TNF)-α and intercellular adhesion molecule 1 (ICAM-1). In addition, enhanced expression of the COMMD3 gene was reported in a particular type of leukemia (Mulaw et al., 2012). EBLN insertion in the hsEBLN-1 locus may downregulate the expression of the COMMD3 gene and thereby potentiate the NF-kB pathway (Honda and Tomonaga, 2016). Cancer cells are known to induce IFNs, which mediate anti-tumor effects on particular types of tumors, such as renal cell carcinoma, and are therefore used in clinical anti-cancer therapy (Müller et al., 2017; Wu et al., 2017). Taken together, hsEBLN-1 may exert anti-tumor effects via the COMMD3-NF-kB-IFN pathway. Further studies are required to understand the contribution of EBLNs to immune modulation during oncogenesis.

Possible Involvement of Retrotransposon-Virus Interactions in Carcinogenesis

As described above, non-retroviral RNA virus-related sequences in the genome are possibly generated by a retrotransposon machinery (Horie et al., 2010; Shimizu et al., 2014). In other words, retrotransposons are a major driving force for generating such EVEs. Therefore, it is important to understand the interactions between retrotransposons and viruses. Among retrotransposons, L1s constitute approximately 17% of the human genome (Lander et al., 2001). Most L1s are 5′ truncated and therefore defective in retrotransposition, whereas 80–100 copies are still retrotransposition-competent and utilize a “copy-and-paste” mechanism to retrotranspose to new genomic loci (Beck et al., 2010; Brouha et al., 2003). L1 is also responsible for the production of non-retroviral RNA virus elements in the host genome as described. Thus, dysregulation of L1s is considered a major source of endogenous insertional mutagenesis in humans (Levin and Moran, 2011; Burns and Boeke, 2012). Indeed, L1 retrotransposition occurs not only in germ line cells and pluripotent stem cells (van den Hurk et al., 2007; Beck et al., 2011; Levin and Moran, 2011; Klawitter et al., 2016) but also in cancer cells (Iskow et al., 2010; Goodier, 2014). Furthermore, although it is unclear whether L1s are activated in normal cells before clonal expansion or in cancer cells during the later stages of carcinogenesis (Goodier, 2014), many epidemiological studies suggest a linkage between dysregulated L1 expression and cancers (Shukla et al., 2013; Rodić et al., 2014; Harada et al., 2015). Once L1 or L1-mediated viral insertions occur around oncogenes or tumor suppressor genes, some of these insertions may confer survival and/or proliferative advantages to the cells, thereby enhancing the various steps of carcinogenesis. Consistent with this idea, transposon-based insertional mutagenesis has been shown to induce virtually any kind of cancer in mice (Dupuy et al., 2005, 2009; Rad et al., 2010). Furthermore, several tumor viruses are reported to activate transcription of retrotransposons, such as endogenous retroviruses and short interspersed nuclear elements (SINEs). For example, Marek’s disease virus, an avian tumor virus, is reported to induce expression of an endogenous retrovirus (Hu et al., 2017), and murine gammaherpesvirus 68, another tumor virus, also activates transcription of SINEs (Tucker and Glaunsinger, 2017). These observations may emphasize the significance of retrotransposon activation in tumor virus-related carcinogenesis.

Conclusion and Perspective

This article has presented a current view of the possible contributions of hepadnavirus and bornavirus insertions in the genome to cancer formation. The presented lines of evidence suggest potential links between these viral sequences and cancers. However, current knowledge in this field is still poor, and there are many questions to be addressed. Although several genes recurrently targeted by HBV insertions have been identified, the precise role of most of them in tumorigenesis remains unclear. Among the HBV integration sties identified so far, only a limited number of cellular-HBV chimeric proteins/transcripts have demonstrated the oncogenic potential. Further accumulation of examples of recurrent HBV insertion sites in the host genome or recurrent chimeric transcripts specific to hepatitis virus-related HCC will be promising to understand the contribution of HBV insertions to HCC etiology. Regarding links between EBLs and cancers, the information is more limited. Epidemiological studies on the links between EBL mutations and cancers are clearly required. Furthermore, the causal relationship between such EBL mutations and cancers should be demonstrated in future.

Although a definitive role for tumor viruses in retrotransposon activation has not been established thus far, investigating a possible link between L1 activation and tumor viruses, especially HBV, would be of considerable interest because L1 hypomethylation or some L1 chimeric transcripts are associated with poor prognosis in HCC (Honda, 2016). Hypomethylation of the L1 loci may upregulate L1 expression, potentially removing an obstacle to L1 transposition in liver cells. Once L1s are activated, any potential disruption of tumor suppressor genes induced by L1 retrotransposition could contribute to the development of HCC. Indeed, L1 has been shown to be a crucial source of mutations that can reduce the tumor-suppressive capacity of somatic cells (Shukla et al., 2013).

Future studies regarding the above links may open a new avenue for the development of novel therapeutics, such as epigenetic modification of viral sequences in the genome, for tumor virus-related cancers. Also, such studies will provide novel insights into the biological roles of EVEs in the cells.

Author Contributions

TH wrote the manuscript, confirms being the sole contributor of this work and approved it for publication.

Conflict of Interest Statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This work was supported in part by JSPS KAKENHI Grant Number JP15K08496, the Program on the Innovative Development and the Application of New Drugs for Hepatitis B from Japan Agency for Medical Research and Development (AMED), and grants from the Takeda Science Foundation, Senri Life Science Foundation, Suzuken Memorial Foundation, and Kobayashi International Scholarship Foundation.

References

  1. Aly H. H., Shimotohno K., Hijikata M., Seya T. (2012). In vitro models for analysis of the hepatitis C virus life cycle. Microbiol. Immunol. 56 1–9. 10.1111/j.1348-0421.2011.00403.x [DOI] [PubMed] [Google Scholar]
  2. Beck C. R., Collier P., Macfarlane C., Malig M., Kidd J. M., Eichler E. E., et al. (2010). LINE-1 retrotransposition activity in human genomes. Cell 141 1159–1170. 10.1016/j.cell.2010.05.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beck C. R., Garcia-Perez J. L., Badge R. M., Moran J. V. (2011). LINE-1 elements in structural variation and disease. Annu. Rev. Genomics Hum. Genet. 12 187–215. 10.1146/annurev-genom-082509-141802 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beck J., Nassal M. (2007). Hepatitis B virus replication. World J. Gastroenterol. 13 48–64. 10.3748/wjg.v13.i1.48 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brouha B., Schustak J., Badge R. M., Lutz-Prigge S., Farley A. H., Moran J. V., et al. (2003). Hot L1s account for the bulk of retrotransposition in the human population. Proc. Natl. Acad. Sci. U.S.A. 100 5280–5285. 10.1073/pnas.0831042100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Burns K. H., Boeke J. D. (2012). Human transposon tectonics. Cell 149 740–752. 10.1016/j.cell.2012.04.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Burstein E., Hoberg J. E., Wilkinson A. S., Rumble J. M., Csomos R. A., Komarck C. M., et al. (2005). COMMD proteins, a novel family of structural and functional homologs of MURR1. J. Biol. Chem. 280 22222–22232. 10.1074/jbc.M501928200 [DOI] [PubMed] [Google Scholar]
  8. Ding D., Lou X., Hua D., Yu W., Li L., Wang J., et al. (2012). Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLOS Genet. 8:e1003065. 10.1371/journal.pgen.1003065 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dupuy A. J., Akagi K., Largaespada D. A., Copeland N. G., Jenkins N. A. (2005). Mammalian mutagenesis using a highly mobile somatic sleeping beauty transposon system. Nature 436 221–226. 10.1038/nature03691 [DOI] [PubMed] [Google Scholar]
  10. Dupuy A. J., Rogers L. M., Kim J., Nannapaneni K., Starr T. K., Liu P., et al. (2009). A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res. 69 8150–8156. 10.1158/0008-5472.CAN-09-1135 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ewing R. M., Chu P., Elisma F., Li H., Taylor P., Climie S., et al. (2007). Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol. Syst. Biol. 3:89. 10.1038/msb4100134 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ferber M. J., Montoya D. P., Yu C., Aderca I., McGee A., Thorland E. C., et al. (2003). Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 22 3813–3820. 10.1038/sj.onc.1206528 [DOI] [PubMed] [Google Scholar]
  13. Forner A., Llovet J. M., Bruix J. (2012). Hepatocellular carcinoma. Lancet 379 1245–1255. 10.1016/S0140-6736(11)61347-0 [DOI] [PubMed] [Google Scholar]
  14. Fujimoto A., Totoki Y., Abe T., Boroevich K. A., Hosoda F., Nguyen H. H., et al. (2012). Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44 760–764. 10.1038/ng.2291 [DOI] [PubMed] [Google Scholar]
  15. Fujino K., Horie M., Honda T., Merriman D. K., Tomonaga K. (2014). Inhibition of Borna disease virus replication by an endogenous bornavirus-like element in the ground squirrel genome. Proc. Natl. Acad. Sci. U.S.A. 111 13175–13180. 10.1073/pnas.1407046111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Geuking M. B., Weber J., Dewannieux M., Gorelik E., Heidmann T., Hengartner H., et al. (2009). Recombination of retrotransposon and exogenous RNA virus results in nonretroviral cDNA integration. Science 323 393–396. 10.1126/science.1167375 [DOI] [PubMed] [Google Scholar]
  17. Gonzalez-Cao M., Iduma P., Karachaliou N., Santarpia M., Blanco J., Rosell R. (2016). Human endogenous retroviruses and cancer. Cancer Biol. Med. 13 483–488. 10.20892/j.issn.2095-3941.2016.0080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Goodier J. L. (2014). Retrotransposition in tumors and brains. Mob. DNA 5:11. 10.1186/1759-8753-5-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Grakoui A., Wychowski C., Lin C., Feinstone S. M., Rice C. M. (1993). Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67 1385–1395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gramolelli S., Ojala P. M. (2017). Kaposi’s sarcoma herpesvirus-induced endothelial cell reprogramming supports viral persistence and contributes to Kaposi’s sarcoma tumorigenesis. Curr. Opin. Virol. 26 156–162. 10.1016/j.coviro.2017.09.002 [DOI] [PubMed] [Google Scholar]
  21. Gravel A., Dubuc I., Morissette G., Sedlak R. H., Jerome K. R., Flamand L. (2015). Inherited chromosomally integrated human herpesvirus 6 as a predisposing risk factor for the development of angina pectoris. Proc. Natl. Acad. Sci. U.S.A. 112 8058–8063. 10.1073/pnas.1502741112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Harada K., Baba Y., Ishimoto T., Chikamoto A., Kosumi K., Hayashi H., et al. (2015). LINE-1 methylation level and patient prognosis in a database of 208 hepatocellular carcinomas. Ann. Surg. Oncol. 22 1280–1287. 10.1245/s10434-014-4134-3 [DOI] [PubMed] [Google Scholar]
  23. He P., Sun L., Zhu D., Zhang H., Zhang L., Guo Y., et al. (2016). Knock-down of endogenous bornavirus-like nucleoprotein 1 inhibits cell growth and induces apoptosis in human oligodendroglia cells. Int. J. Mol. Sci. 17:435. 10.3390/ijms17040435 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hijikata M., Kato N., Ootsuyama Y., Nakagawa M., Shimotohno K. (1991). Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl. Acad. Sci. U.S.A. 88 5547–5551. 10.1073/pnas.88.13.5547 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hino O., Tabata S., Hotta Y. (1991). Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. Proc. Natl. Acad. Sci. U.S.A. 88 9248–9252. 10.1073/pnas.88.20.9248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Holmes E. C. (2011). The evolution of endogenous viral elements. Cell Host Microbe 10 368–377. 10.1016/j.chom.2011.09.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Honda T. (2016). Links between human LINE-1 retrotransposons and hepatitis virus-related hepatocellular carcinoma. Front. Chem. 4:21. 10.3389/fchem.2016.00021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Honda T., Tomonaga K. (2013). Nucleocytoplasmic shuttling of viral proteins in Borna disease virus infection. Viruses 5 1978–1990. 10.3390/v5081978 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Honda T., Tomonaga K. (2016). Endogenous non-retroviral RNA virus elements evidence a novel type of antiviral immunity. Mob. Genetic. Elements 6:e1165785. 10.1080/2159256X.2016.1165785 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Horie M., Honda T., Suzuki Y., Kobayashi Y., Daito T., Oshida T., et al. (2010). Endogenous non-retroviral RNA virus elements in mammalian genomes. Nature 463 84–87. 10.1038/nature08695 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hu X., Zhu W., Chen S., Liu Y., Sun Z., Geng T., et al. (2017). Expression patterns of endogenous avian retrovirus ALVE1 and its response to infection with exogenous avian tumour viruses. Arch. Virol. 162 89–101. 10.1007/s00705-016-3086-2 [DOI] [PubMed] [Google Scholar]
  32. Iskow R. C., McCabe M. T., Mills R. E., Torene S., Pittard W. S., Neuwald A. F., et al. (2010). Natural mutagenesis of human genomes by endogenous retrotransposons. Cell 141 1253–1261. 10.1016/j.cell.2010.05.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D. (2011). Global cancer statistics. CA Cancer J. Clin. 61 69–90. 10.3322/caac.20107 [DOI] [PubMed] [Google Scholar]
  34. Jiang Z., Jhunjhunwala S., Liu J., Haverty P. M., Kennemer M. I., Guan Y., et al. (2012). The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res. 22 593–601. 10.1101/gr.133926.111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Katzourakis A., Gifford R. J. (2010). Endogenous viral elements in animal genomes. PLOS Genet. 6:e1001191. 10.1371/journal.pgen.1001191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Klawitter S., Fuchs N. V., Upton K. R., Muñoz-Lopez M., Shukla R., Wang J., et al. (2016). Reprogramming triggers endogenous L1 and Alu retrotransposition in human induced pluripotent stem cells. Nat. Commun. 7:10286. 10.1038/ncomms10286 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Lander E. S., Linton L. M., Birren B., Nusbaum C., Zody M. C., Baldwin J., et al. (2001). Initial sequencing and analysis of the human genome. Nature 409 860–921. 10.1038/35057062 [DOI] [PubMed] [Google Scholar]
  38. Lando M., Wilting S. M., Snipstad K., Clancy T., Bierkens M., Aarnes E.-K., et al. (2013). Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling. J. Pathol. 230 59–69. 10.1002/path.4168 [DOI] [PubMed] [Google Scholar]
  39. Lau C.-C., Sun T., Ching A. K. K., He M., Li J.-W., Wong A. M., et al. (2014). Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell 25 335–349. 10.1016/j.ccr.2014.01.030 [DOI] [PubMed] [Google Scholar]
  40. Levin H. L., Moran J. V. (2011). Dynamic interactions between transposable elements and their hosts. Nat. Rev. Genet. 12 615–627. 10.1038/nrg3030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Lleonart M. E., Grodzicki R., Graifer D. M., Lyakhovich A. (2017). Mitochondrial dysfunction and potential anticancer therapy. Med. Res. Rev. 37 1275–1298. 10.1002/med.21459 [DOI] [PubMed] [Google Scholar]
  42. McBride A. A. (2017). Oncogenic human papillomaviruses. Philos. Trans. R. Soc. B Biol. Sci. 372:20160273. 10.1098/rstb.2016.0273 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Mulaw M. A., Krause A. J., Deshpande A. J., Krause L. F., Rouhi A., La Starza R., et al. (2012). CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12. Leukemia 26 1012–1019. 10.1038/leu.2011.307 [DOI] [PubMed] [Google Scholar]
  44. Müller L., Aigner P., Stoiber D. (2017). Type I interferons and natural killer cell regulation in cancer. Front. Immunol. 8:304. 10.3389/fimmu.2017.00304 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Myers K. N., Barone G., Ganesh A., Staples C. J., Howard A. E., Beveridge R. D., et al. (2016). The bornavirus-derived human protein EBLN1 promotes efficient cell cycle transit, microtubule organisation and genome stability. Sci. Rep. 6:35548. 10.1038/srep35548 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Nguyen D. H., Ludgate L., Hu J. (2008). Hepatitis B virus-cell interactions and pathogenesis. J. Cell. Physiol. 216 289–294. 10.1002/jcp.21416 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Pancholi N. J., Price A. M., Weitzman M. D. (2017). Take your PIKK: tumour viruses and DNA damage response pathways. Philos. Trans. R. Soc. B Biol. Sci. 372:20160269. 10.1098/rstb.2016.0269 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Parkin D. M. (2006). The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118 3030–3044. 10.1002/ijc.21731 [DOI] [PubMed] [Google Scholar]
  49. Parrish N. F., Tomonaga K. (2016). Endogenized viral sequences in mammals. Curr. Opin. Microbiol. 31 176–183. 10.1016/j.mib.2016.03.002 [DOI] [PubMed] [Google Scholar]
  50. Rad R., Rad L., Wang W., Cadinanos J., Vassiliou G., Rice S., et al. (2010). PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science 330 1104–1107. 10.1126/science.1193004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Renieri A., Mencarelli M. A., Cetta F., Baldassarri M., Mari F., Furini S., et al. (2014). Oligogenic germline mutations identified in early non-smokers lung adenocarcinoma patients. Lung Cancer 85 168–174. 10.1016/j.lungcan.2014.05.020 [DOI] [PubMed] [Google Scholar]
  52. Rodić N., Sharma R., Sharma R., Zampella J., Dai L., Taylor M. S., et al. (2014). Long interspersed element-1 protein expression is a hallmark of many human cancers. Am. J. Pathol. 184 1280–1286. 10.1016/j.ajpath.2014.01.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Shen Z., Liu Y., Luo M., Wang W., Liu J., Liu W., et al. (2016). Nuclear factor Y regulates ancient budgerigar hepadnavirus core promoter activity. Biochem. Biophys. Res. Commun. 478 825–830. 10.1016/j.bbrc.2016.08.032 [DOI] [PubMed] [Google Scholar]
  54. Shimizu A., Nakatani Y., Nakamura T., Jinno-Oue A., Ishikawa O., Boeke J. D., et al. (2014). Characterisation of cytoplasmic DNA complementary to non-retroviral RNA viruses in human cells. Sci. Rep. 4:5074. 10.1038/srep05074 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Shukla R., Upton K. R., Muñoz-Lopez M., Gerhardt D. J., Fisher M. E., Nguyen T., et al. (2013). Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. Cell 153 101–111. 10.1016/j.cell.2013.02.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Silva E., Marques S., Osório H., Carvalheira J., Thompson G. (2012). Endogenous hepatitis C virus homolog fragments in European rabbit and hare genomes replicate in cell culture. PLOS ONE 7:e49820. 10.1371/journal.pone.0049820 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Snow C. J., Paschal B. M. (2014). “Roles of the nucleoporin Tpr in cancer and aging,” in Advances in Experimental Medicine and Biology, eds Cohen I. R., Lajtha A., Lambris J. D., Paoletti R., Rezaei N. (New York, NY: Springer Science+Business Media; ), 309–322. 10.1007/978-1-4899-8032-8_14 [DOI] [PubMed] [Google Scholar]
  58. Sofuku K., Parrish N. F., Honda T., Tomonaga K. (2015). Transcription profiling demonstrates epigenetic control of non-retroviral RNA virus-derived elements in the human genome. Cell Rep. 12 1548–1554. 10.1016/j.celrep.2015.08.007 [DOI] [PubMed] [Google Scholar]
  59. Sung W.-K., Zheng H., Li S., Chen R., Liu X., Li Y., et al. (2012). Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 44 765–769. 10.1038/ng.2295 [DOI] [PubMed] [Google Scholar]
  60. Suntsova M., Garazha A., Ivanova A., Kaminsky D., Zhavoronkov A., Buzdin A. (2015). Molecular functions of human endogenous retroviruses in health and disease. Cell. Mol. Life Sci. 72 3653–3675. 10.1007/s00018-015-1947-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Tateishi R., Omata M. (2012). Hepatocellular carcinoma in 2011: genomics in hepatocellular carcinoma–a big step forward. Nat. Rev. Gastroenterol. Hepatol. 9 69–70. 10.1038/nrgastro.2011.255 [DOI] [PubMed] [Google Scholar]
  62. Tucker J. M., Glaunsinger B. A. (2017). Host noncoding retrotransposons induced by DNA viruses: a SINE of infection? J. Virol. 91:e00982-17. 10.1128/JVI.00982-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. van den Hurk J. A. J. M., Meij I. C., Seleme M., del C., Kano H., Nikopoulos K., et al. (2007). L1 retrotransposition can occur early in human embryonic development. Hum. Mol. Genet. 16 1587–1592. 10.1093/hmg/ddm108 [DOI] [PubMed] [Google Scholar]
  64. Whittaker S., Marais R., Zhu A. X. (2010). The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29 4989–5005. 10.1038/onc.2010.236 [DOI] [PubMed] [Google Scholar]
  65. Wu Y., Wu X., Wu L., Wang X., Liu Z. (2017). The anticancer functions of RIG-I-like receptors, RIG-I, and MDA5 and their applications in cancer therapy. Transl. Res. 190 51–60. 10.1016/j.trsl.2017.08.004 [DOI] [PubMed] [Google Scholar]
  66. Zemer R., Kitay Cohen Y., Naftaly T., Klein A. (2008). Presence of hepatitis C virus DNA sequences in the DNA of infected patients. Eur. J. Clin. Invest. 38 845–848. 10.1111/j.1365-2362.2008.02029.x [DOI] [PubMed] [Google Scholar]
  67. Zhao J.-W., Fang F., Guo Y., Zhu T.-L., Yu Y.-Y., Kong F.-F., et al. (2016). HPV16 integration probably contributes to cervical oncogenesis through interrupting tumor suppressor genes and inducing chromosome instability. J. Exp. Clin. Cancer Res. 35:180. 10.1186/s13046-016-0454-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Microbiology are provided here courtesy of Frontiers Media SA

RESOURCES